US Has Opportunity To Lead On Ophthalmic Biosimilars
Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report
With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology – in an exclusive interview with Generics Bulletin.
